Current trends in chronic hepatitis B management: Results of a questionnaire

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 10, 2009, Pages 1177-1183

  Les, Iñigo ^a   García Martínez, Rita ^a   Córdoba, Juan ^a   Quintana, Manuel ^a   Esteban, Rafael ^a   Buti, María ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiviral treatment; Chronic hepatitis B; Diagnosis; HBV drug resistance; Interferon; Management; Nucleoside analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; HEPATITIS B VACCINE; PHOSPHONIC ACID DERIVATIVE;

ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; CLINICAL DECISION MAKING; CONTINUING EDUCATION; DISEASE CARRIER; DNA DETERMINATION; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOSUPPRESSIVE TREATMENT; KNOWLEDGE; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; SPAIN; TREATMENT INDICATION; UNIVERSITY HOSPITAL; ADULT; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CLINICAL COMPETENCE; CLINICAL PRACTICE; DRUG ADMINISTRATION; FAMILY HEALTH; HEPATITIS B, CHRONIC; HUMAN; LIVER; MALE; MIDDLE AGED; PATHOLOGY; TRENDS; UTILIZATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOPSY; CLINICAL COMPETENCE; DRUG ADMINISTRATION SCHEDULE; FAMILY HEALTH; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SPAIN;

EID: 70349732026     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283154f3a     Document Type: Article

References (31)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
2. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research. Hepatology 2007; 45: 1056-1075. (Pubitemid 46646501)
3. Dienstag JL, Schiff ER,Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263. (Pubitemid 29489740)
4. Chan HL,Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12:345-353. (Pubitemid 46787979)
5. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816. (Pubitemid 36245757)
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B. N Engl J Med 2003; 348:800-807. (Pubitemid 36245756)
7. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
8. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
9. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S,Wang Y, et al. Telvibudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
10. Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007; 11:851-868.
11. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HbeAg-positive chronic hepatitis. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
12. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HbeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217. (Pubitemid 39296307)
13. Van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Adefovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318-325.
14. Bruguera M, Bañares R, Córdoba J, Jardi R, González Lahoz J, Ladero JM, et al. Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B and C virus infections. Gastroenterol Hepatol 2006; 29 (Suppl 2):216S-230S. (Pubitemid 47250766)
15. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children and adolescents. MMWR Recomm Rep 2005; 54:1-31.
16. Mast EE,Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33.
17. Toro C, Jiménez V, Rodríguez C, Del Romero J, Rodés B, Holguín A, et al. Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. J Med Virol 2006; 78: 1599-1608. (Pubitemid 44672503)
18. Shehab TM, Sonnad SS, Jeffries M, Gunaratnum N, Lok AS. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 1999; 30:794-800. (Pubitemid 29409426)
19. Peksen Y, Canbaz S, Leblebicioglu H, Sunbul M, Esen S, Sunter AT. Primary care physician's approach to diagnosis and treatment of hepatitis B and hepatitis C patients. BMC Gastroenterol 2004; 4:3-8. (Pubitemid 38671547)
20. Tan NC, Cheah SL. What barriers do primary care physicians face in the management of patients with chronic hepatitis B infection in primary care? Singapore Med J 2005; 46:333-339.
21. Marcellin P, Cadranel JF, Fontanges T, Poynard T, Pol S, Trepo C, et al. Which patients with chronic hepatitis B are treated and how: a crosssectional study in France on 1790 patients. J Hepatol 2007; 46 (Suppl 1): 1S-346S.
22. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8:167-178. Epub 28 Nov 2007. (Pubitemid 351249242)
23. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62:299-307. (Pubitemid 30740118)
24. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220. (Pubitemid 43303989)
25. Del Poggio P, Jamoletti C, Zaccanelli M. Preemptive lamivudine in hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749.
26. Wonk DK, Cheung AM, ÓRourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323. (Pubitemid 23319890)
27. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305. (Pubitemid 36801917)
28. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34:306-313. (Pubitemid 32176454)
29. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101. (Pubitemid 38040727)
30. Chen CH,Wang JH, Lee CM, Hung CH, Hu TH,Wang JC, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11:771-778. (Pubitemid 44497172)
31. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. Epub 2 Sep 2007. (Pubitemid 350047463)